

Kansas Medicaid Preferred Drug List Advisory Committee

Rules for Public Forum

Pursuant to the Kansas Open Meetings Act (K.S.A. 75-4317), meetings of the Preferred Drug List Advisory Committee are open to the public. In order to facilitate organized and efficient meetings, the following rules for public forum apply:

- Non-members of the committee and other interested parties will be recognized by the Committee Chairperson only during designated public comment periods.
- Prior to final committee action on a drug or drug class coverage decision, there will be a designated public comment period that will be clearly identified on the meeting agenda.
- Pharmaceutical manufacturers or other interested parties will be given a total of 5 minutes per drug in the therapeutic drug class under discussion. This will be during the designated public comment period. The following will apply:
 - 1) This is to provide key points outlining the evidence-based value of the drug product.
 - 2) A Conflict of Interest Form must be completed, signed and given to the chairperson of the Preferred Drug List (PDL) Advisory Committee prior to speaking.
 - 3) A copy of all handouts, slide shows, etc. to be presented at the PDL Meeting must be submitted to Mary Lesperance, DHPF, Pharmacy Program Manager 900 SW Jackson, Suite 900, Topeka, KS, 66612, mho@srskansas.org seven (7) days prior to the scheduled meeting.
 - 4) The 5 minute allotment for each drug will be divided by the number of people speaking.
 - 5) If any audio-visual equipment is needed for a presentation, the equipment must be provided by the presenter.
- Following the brief presentations, time will be allowed for committee members to ask questions of the presenter.
- The Committee Chairperson will serve as the designated timekeeper for presentations.